Pharma and biotech collaboration
Program strategy, biomarker framing, and translational support for immuno-oncology assets.
MIORG engages with pharma, biotech, diagnostic organizations, academic groups, hospitals, and translational research partners looking to strengthen biomarker strategy, resistance biology, or combination development in immuno-oncology.
Science-driven organizations seeking disciplined oncology collaboration with practical translational value.
Program strategy, biomarker framing, and translational support for immuno-oncology assets.
Co-development or validation dialogue around predictive immune profiling and companion diagnostic tools.
Clinically grounded biomarker work, cohort interpretation, and translational planning.
Joint research discussions around immune resistance, antigen presentation, and dendritic cell biology.
Conversations around strategic financing, translational milestones, and non-dilutive funding opportunities.
Targeted scientific consulting for biomarker, tumor immunology, and combination design questions.
MIORG welcomes outreach from organizations interested in predictive oncology, combination immunotherapy, and translational cancer immunology collaboration.